Alecensa (alectinib) Patient Assistance Program
Don’t let the high cost of brand second-generation ALK inhibitor disrupt your ALK-positive lung cancer treatment. We help eligible patients access Alecensa (alectinib capsules) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Alecensa (alectinib) is FDA-approved for adjuvant treatment after tumor resection of ALK-positive NSCLC, first-line treatment of ALK-positive metastatic NSCLC, and treatment of metastatic ALK-positive NSCLC that progressed on or are intolerant of crizotinib. Second-generation ALK tyrosine kinase inhibitor with excellent CNS penetration — established as first-line standard for ALK-positive NSCLC.
- Without assistance, Alecensa costs commonly run approximately $19,000–$22,000 per month.
- Through AffordMyPrescriptions, qualifying patients can access Alecensa for a flat $69.95 per month.
- Other ALK inhibitors: crizotinib (Xalkori — first-generation, generic available, inferior outcomes vs second-generation), brigatinib (Alunbrig), ceritinib (Zykadia), lorlatinib (Lorbrena — third-generation, broadest mutation coverage). Per ALEX, ALTA-1L, J-ALEX, and CROWN trials, second-generation ALK TKIs (alectinib, brigatinib, lorlatinib) have demonstrated superiority over crizotinib in first-line ALK-positive NSCLC. Tumor molecular testing (ALK FISH or NGS) essential. For other oncogenes in NSCLC: EGFR (Tagrisso, Tarceva, Iressa, Gilotrif), ROS1 (Rozlytrek, Xalkori, Lorbrena, Augtyro), KRAS G12C (Lumakras, Krazati), BRAF V600E (Tafinlar+Mekinist), MET exon 14 (Tabrecta, Tepmetko), RET (Retevmo, Gavreto), HER2 (Enhertu), NTRK (Vitrakvi, Rozlytrek).
What is Alecensa Prescription Assistance Program?
The Alecensa Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Alecensa (used for ALK-positive non-small cell lung cancer) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but the enrollment process involves detailed applications, oncology coordination, ALK rearrangement documentation, supporting documentation, and ongoing renewal — which can be overwhelming when you are managing lung cancer.
At AffordMyPrescriptions, our Patient Advocates handle the entire Alecensa PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your oncologist for required medical documentation (typically including tumor ALK testing results, prior treatment history, and clinical criteria), follow up with the manufacturer’s program until approval, manage your refills, and handle annual re-certification — so you never face a gap in your Alecensa ALK inhibitor therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Alecensa enrollment — from the initial application through ongoing refills and annual re-enrollment — so you never face a gap in your ALK-positive lung cancer treatment.
Pharmacy Price Comparison
- Without assistance, Alecensa costs nearly $20,000 per month at specialty pharmacies. Discount cards and pharmacy coupons offer minimal relief at this price point, but a Patient Assistance Program can make this targeted lung cancer therapy accessible if you qualify. The table below compares typical retail pricing across major pharmacies to what you'd pay with our Alecensa advocacy service:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Lorbrena (3rd-gen alt) | ~$22,000/mo | 3rd-gen broader resistance |
| Walgreens | ~$21,500/mo | Save substantially |
| CVS Pharmacy | ~$22,000/mo | Save substantially |
| Walmart | ~$19,500/mo | Save substantially |
| Specialty pharmacy | ~$19,000/mo | Save substantially |
| Generic crizotinib (alt) | ~$2,000/mo | Generic 1st-gen alt — inferior |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Alecensa — independent of dosage or retail price.
Why choose us For Your Alecensa Prescription Program?
The Alecensa Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management — applications that are commonly delayed or denied when paperwork is incomplete. Our $69.95 per month covers full advocacy: applications, doctor coordination, documentation, refill management, and re-enrollment — so you focus on your health, not paperwork. Alecensa is the established first-line standard for ALK-positive NSCLC due to superior PFS, CNS efficacy, and tolerability vs crizotinib.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Alecensa assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Alecensa is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Alecensa:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $19,000–$22,000 per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Alecensa assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Alecensa Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Alecensa:
Alecensa is a second-generation ALK inhibitor designed for enhanced ALK selectivity and excellent CNS penetration — critical because brain metastases occur in ~30% of ALK-positive NSCLC patients. The ALEX and J-ALEX trials established Alecensa’s superiority over crizotinib in PFS, CNS activity, and tolerability — making it standard first-line therapy.
How It Works:
ALK (anaplastic lymphoma kinase) rearrangements (typically EML4-ALK fusions) drive tumor growth in approximately 3–7% of NSCLC. ALK fusions produce constitutively active fusion proteins that signal through downstream pathways (RAS/MAPK, PI3K/AKT, JAK/STAT) driving proliferation and survival. Alectinib binds and inhibits ALK kinase activity — blocking downstream proliferation and survival signaling. Better CNS penetration than first-generation crizotinib (high BBB permeability — substantially reduces brain metastasis progression and improves CNS disease control). Active against many crizotinib-resistance mutations. Standard first-line therapy in ALK-positive NSCLC and adjuvant after resection (ALINA trial established adjuvant role).
Form and Use:
Alecensa 150 mg capsules. Recommended dose 600 mg (4 capsules) twice daily with food. Continue until disease progression or unacceptable toxicity (advanced setting) or up to 2 years (adjuvant setting per ALINA). Dose adjustments for hepatotoxicity, ILD/pneumonitis, bradycardia, severe myalgia/CPK elevation, hemolytic anemia. Periodic LFTs (especially first 3 months), CBC, CPK, ECG, bilirubin monitoring.
Generic Availability:
No generic Alecensa. Other ALK inhibitors: crizotinib (Xalkori — first-generation, generic available, inferior outcomes vs second-generation per direct trials), brigatinib (Alunbrig — second-generation, alternative first-line per ALTA-1L), ceritinib (Zykadia — second-generation, more GI toxicity), lorlatinib (Lorbrena — third-generation, broadest mutation coverage, CNS-active, more CV/cognitive side effects — alternative first-line per CROWN trial). Choice often by insurance and patient-specific factors. Tumor molecular testing (ALK FISH, IHC, NGS) essential for diagnosis. Other oncogenic driver therapies for NSCLC depending on tumor molecular profile: EGFR TKIs (Tagrisso, Tarceva generic, Gilotrif, Rybrevant for exon 20), ROS1 (Rozlytrek, Xalkori, Lorbrena, Augtyro), KRAS G12C (Lumakras, Krazati), BRAF V600E (Tafinlar+Mekinist), MET exon 14 (Tabrecta, Tepmetko), RET (Retevmo, Gavreto), HER2 (Enhertu), NTRK (Vitrakvi, Rozlytrek). For wild-type NSCLC: pembrolizumab (Keytruda) ± chemo, atezolizumab, durvalumab, nivolumab + ipilimumab combinations.
Warnings:
Hepatotoxicity (severe ALT/AST elevations, possible drug-induced liver injury — monitor LFTs frequently first 3 months and periodically thereafter), interstitial lung disease and pneumonitis (sometimes fatal — evaluate any new respiratory symptoms), bradycardia (monitor heart rate especially with concurrent rate-lowering medications), severe myalgia and CPK elevations (monitor CPK; counsel patients to report severe muscle symptoms), hemolytic anemia (rare but reported — monitor CBC), embryo-fetal toxicity, photosensitivity. Drug interactions: minimal CYP3A4 metabolism — relatively few strong interactions, though strong inhibitors may still affect levels modestly; manage strong inducers per protocol. Avoid prolonged sun exposure.
FAQ (Frequently Asked Questions)
How much does Alecensa cost without insurance?
$19,000–$22,000 per month. Annual cost exceeds $250,000 without assistance. Specialty pharmacy and Patient Assistance Programs are essential for most patients.
Is Alecensa considered chemotherapy?
No — Alecensa is a targeted oral therapy (ALK tyrosine kinase inhibitor) — not traditional cytotoxic chemotherapy. Different toxicity profile from chemotherapy with generally better tolerability.
Why is ALK testing required before starting Alecensa?
Alecensa is specifically active against ALK-fusion-positive NSCLC. Tumor ALK testing (FISH, IHC, or comprehensive NGS) identifies patients who will benefit. NCCN guidelines recommend comprehensive biomarker testing (EGFR, ALK, ROS1, BRAF, KRAS, NTRK, RET, MET, HER2, PD-L1) for all metastatic non-squamous NSCLC to guide treatment selection.
What is the difference between Alecensa and crizotinib (Xalkori)?
Both target ALK. Crizotinib is first-generation — broader off-target effects, less CNS penetration, inferior outcomes vs second-generation. Alecensa is second-generation — improved ALK selectivity, much better CNS penetration (critical for brain metastasis prevention/treatment), better tolerability, and superior PFS in ALEX and J-ALEX trials. Generic crizotinib is much cheaper but offers worse outcomes — Alecensa is current first-line standard.
What is the difference between Alecensa, brigatinib (Alunbrig), and lorlatinib (Lorbrena)?
All effective second/third-generation ALK inhibitors. Alecensa: second-generation, twice-daily with food, established first-line standard. Brigatinib (Alunbrig): second-generation, once-daily, requires 7-day lead-in, ILD risk. Lorlatinib (Lorbrena): third-generation, once-daily, broadest mutation coverage, more CV/cognitive side effects. Choice often by insurance and patient-specific factors.
Take Control of Your Medication Costs
Targeted ALK inhibitor therapy for ALK-positive lung cancer should not be derailed by cost. Alecensa is the established first-line standard with the best CNS efficacy and tolerability. Our Alecensa advocacy team is ready to verify your eligibility, complete the manufacturer application on your behalf, and manage your prescription through approval, delivery, and renewal — for a flat $69.95 per month. If we cannot help you access Alecensa through a Patient Assistance Program, you are not charged.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.